Clinical trials: Prodromal Alzheimer's Disease
Alzheimer's Disease
" The Eyes Have it " : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease
Alzheimer's disease (AD) has a prolonged prodromal phase before the stage of dementia. Subtle executive cognitive function deficits can be detected at this early pre-dementia phase, more than 10 years before dementia.
- Trial name
- LYLO (NCT01630525)
- Testing
- Neuropsychological assessment, ophthalmologic checkup, Automated non-invasive oculometry
- Where
- 3 sites in France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Mild Cognitive Impairment, Alzheimer Disease
INTERCEPTOR Project: From MCI to Dementia
In the next years a number of phase 2-3 trials which utilize experimental drugs possibly disease modifying for Alzheimer Dementia will reach their conclusion.
- Trial name
- INTERCEPTOR (NCT03834402)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Catholic University of the Sacred Heart
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Alzheimer's Tau Platform: Regimen A - AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Trial name
- ATP (NCT07167966)
- Testing
- AADvac1, Donanemab
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Paul S. Aisen
Alzheimer's Disease
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment.
- Trial name
- NCT06402838
- Testing
- RO7269162
- Where
- 46 sites in Chile, Denmark and 7 more
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Amyloid Plaque, Beta-Amyloid
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
- Trial name
- NCT05462106
- Testing
- ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 304 people
- Sponsor
- AC Immune SA
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in PACC5 between baseline and +12 month follow up across all four Arms, as…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-FUTURE (NCT04846426)
- Where
- 4 sites in United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Prodromal Alzheimer's Disease, Alzheimer Disease
COGNIFOOD-Changing the Carbohydrate/Fat-ratio to Prevent Cognitive Decline and Alzheimer Pathology: A Pilot Study
A 2-arm (sequence), 2-period, 2-treatments, single blinded (outcome assessor), randomized crossover-trial (12+12 weeks with immediate contrast) comparing a low-carbohydrate-high-fat diet (LCHF) with a high-carbohydrate-low-fat…
- Conditions
- Prodromal Alzheimer's Disease, Alzheimer Disease, Mild Cognitive Impairment, Neurocognitive Disorders
- Trial name
- NCT06105320
- Testing
- LCHF, HCLF
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Alzheimer Disease
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
- Trial name
- NCT01978548
- Testing
- JNJ-54861911 10 mg, JNJ-54861911 50 mg
- Where
- 10 sites in Belgium, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Down Syndrome, Alzheimer Disease
Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21)
TriAL21 study is an interventional, open, one arm, prospective, national and single center study. A total of 200 patients with Down syndrome, aged 35 years and over, without diagnosis of Alzheimer's disease will be enrolled into…
- Trial name
- NCT03901261
- Testing
- Neuro-imaging, Lumbar puncture
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Jerome Lejeune
Alzheimer's Disease
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
The primary objective of this study is to evaluate the safety and tolerability of multiple doses of Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) in participants with prodromal or mild Alzheimer's Disease (AD).
- Trial name
- PRIME (NCT01677572)
- Testing
- Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
- Where
- 32 sites in United States
- Volunteers
- 197 people
- Sponsor
- Biogen
Prodromal Alzheimer's Disease, Mild Cognitive Impairment
Brain Iron Toxicity and Neurodegeneration - A 7T MRI Study
A longitudinal observational neuroimaging study of individuals with Early Onset Alzheimer's disease during the prodromal phase, and matched control group - Ultrahigh Field MRI study at 7T
- Trial name
- BITaN (NCT04992975)
- Testing
- MRI at 7T
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Alzheimer Disease (AD)
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
The study aims to compare tau targeted radiotracers [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
- Trial name
- NCT04566003
- Testing
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Prodromal Alzheimer's Disease
Combined tDCS and Cognitive Training in Alzheimer's
The General Objective of the study is to evaluate the short- and long-term efficacy of combining transcranial Direct Current Stimulation (tDCS) and cognitive training (CT) in patients with mild cognitive impairment due to…
- Trial name
- COMBINA-COG (NCT06861231)
- Testing
- Transcraneal Direct Current Stimulation (tDCS)- Active, Cognitive Training (CT)
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- University of Valencia
Prodromal Alzheimer's Disease, Mild Cognitive Impairment
The Digital Memory Notebook
Compensatory aids (e.g., alarms, calendars) play an important supporting role when completing everyday tasks (e.g., appointments, medication management), and there is a growing body of scientific work suggesting that compensatory…
- Conditions
- Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Subjective Cognitive Complaints
- Trial name
- DMN (NCT04240665)
- Testing
- Digital Memory Notebook (DMN) Application
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Davis
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-US (NCT04928976)
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Prodromal Alzheimer's Disease, Cerebral Vascular Disorder
Hyperbaric Oxygen Therapy for Prodromal Alzheimer´s Disease With Cerebrovascular Disease
Alzheimer´s disease is a devastating illness that effects the patients as well as their family members. Its prevalence increases exponentially and the burden on the healthcare system is enormous.
- Conditions
- Prodromal Alzheimer's Disease, Cerebral Vascular Disorder, Mild Cognitive Impairment, Vascular Cognitive Impairment
- Trial name
- NCT05349318
- Testing
- Hyperbaric oxygen therapy
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with…
- Trial name
- Scarlet Road (NCT01224106)
- Testing
- Gantenerumab
- Where
- 139 sites in United States, Argentina and 22 more
- Volunteers
- 799 people
- Sponsor
- Hoffmann-La Roche